GlassScriptPhysician profile
Daniel Adam Yanes
NPI 1306387584
$43,797.29
in general payments reported to CMS, 2019-2025
24 companies · $18K in 2025
The $18K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $219 · 2022: $3,452 · 2023: $1,603 · 2024: $20K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Food and Beverage: $3,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $36,825.00 |
| Food and Beverage | $3,300.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $40,042.70 | 2022-2025 | Xeomin |
| Abbvie INC. | $1,241.90 | 2021-2025 | Botox, Rinvoq, Skyrizi |
| Amgen INC. | $361.59 | 2021-2024 | Otezla, Enbrel |
| Janssen Biotech, INC. | $358.84 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Incyte Corporation | $353.88 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $264.23 | 2022-2025 | Aklief, Epsolay, Twyneo |
| Sun Pharmaceutical Industries INC. | $179.91 | 2023-2025 | Winlevi, Absorica Ld |
| Lilly USA, LLC | $165.81 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.42 | 2023-2025 | Spevigo |
| Pfizer INC. | $98.32 | 2021-2023 | |
| Genzyme Corporation | $80.97 | 2022-2025 | |
| Genentech USA, INC. | $78.89 | 2021-2025 | Xolair |
| Arcutis Biotherapeutics, INC. | $71.38 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $51.89 | 2025 | |
| Revance Therapeutics, INC. | $45.95 | 2024 | Daxxify |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.06 | 2023-2024 | Jublia, Arazlo, Cabtreo |
| Biofrontera INC. | $40.81 | 2021-2022 | |
| Almirall LLC | $39.47 | 2022-2024 | Klisyri |
| Solta Medical, A Division of Bausch Health US, LLC | $36.41 | 2023-2024 | Fraxel |
| Leo Pharma INC. | $34.75 | 2024 | Adbry |
| Mayne Pharma Commercial LLC | $26.30 | 2022 | |
| Organon LLC | $25.98 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $21.93 | 2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $17.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Yanes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.